Inhibikase Therapeutics Inc (IKT) — Strategic Asset Allocation Index

Latest as of March 2023: 2.1%

Inhibikase Therapeutics Inc (IKT) has a Strategic Asset Allocation Index of 2.1% as of March 2023. Strategic assets (PP&E of $534.75K plus long-term investments of $-) total $534.75K, measured against net assets of $25.32 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.

SAAI

2.1%

Strategic Assets / Net Assets

Strategic Assets

$534.75K

PP&E + LT Investments

PP&E

$534.75K

USD

Net Assets

$25.32 Million

USD

Annual Strategic Asset Allocation Index for Inhibikase Therapeutics Inc (None–None)

The table below presents the year-by-year Strategic Asset Allocation Index for Inhibikase Therapeutics Inc from None to None, covering 0 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see how much is Inhibikase Therapeutics Inc worth.

Year	SAAI	Strategic Assets (USD)	PP&E	LT Investments	Net Assets	Change (pp)

pp = percentage points